Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Kiely (Sheffield (South Yorkshire), United Kingdom), E. Cottreel (Allschwil, Switzerland), N. Galiè (Bologna, Italy), J. Marcus (Amsterdam, Netherlands), A. Peacock (Glasgow, United Kingdom), S. Rosenkranz (Cologne, Germany), A. Swift (Sheffield, United Kingdom), A. Tawakol (Boston, United States of America), A. Torbicki (Otwock, Poland), A. Vonk Noordegraaf (Amsterdam, Netherlands), G. Wetherill (Allschwil, Switzerland), R. Channick (Los Angeles, United States of America). REPAIR: long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH). 3971

Member's Comments

No comment yet.

Related content which might interest you: Carvedilol partially reverses maladaptive remodeling and improves function of the right ventricle (RV) in experimentally-induced pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Effect of sitaxentan on haemodynamics and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Right ventricular (RV) morphometric and ventriculo-vascular (VV) coupling patterns in patients with advanced pulmonary arterial hypertension (PAH) undergoing parenteral treprostinil therapy Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Right ventricular (RV) diastolic function in patients with pulmonary hypertension (PH) due to chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 26s Year: 2002 The right ventricle in pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 476-487 Year: 2014 Bosentan combined with sildenafil prevents right ventricular hypoxia in pulmonary arterial hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 The role of the right ventricle in pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 243-253 Year: 2011 The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH) vs idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Change in right atrial minimal volume is a prognostic marker in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – From microimaging to functional evaluation of the lung Year: 2016 Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Source: Eur Respir J 2015; 45: 1303-1313 Year: 2015 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 More on the right ventricle in pulmonary hypertension Source: Eur Respir J 2015; 45: 33-35 Year: 2015 Isolated diastolic dysfunction of right ventricle: stress-induced pulmonary hypertension Source: Eur Respir J 2008; 31: 475-476 Year: 2008 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Macitentan in pulmonary hypertension due to left ventricular dysfunction Source: Eur Respir J, 51 (2) 1701886; 10.1183/13993003.01886-2017 Year: 2018 Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Haemodynamic evaluation of pulmonary hypertension Source: Eur Respir J 2002; 20: 1314-1331 Year: 2002 Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014